Search hospitals

>

Virginia

>

Richmond

Virginia Commonwealth University

Claim this profile

Richmond, Virginia 23219

Global Leader in Heart Failure

Global Leader in Nonalcoholic Steatohepatitis

Conducts research for Atrial Fibrillation

Conducts research for Non-alcoholic Fatty Liver Disease

Conducts research for Cancer

828 reported clinical trials

79 medical researchers

Photo of Virginia Commonwealth University in RichmondPhoto of Virginia Commonwealth University in RichmondPhoto of Virginia Commonwealth University in Richmond

Summary

Virginia Commonwealth University is a medical facility located in Richmond, Virginia. This center is recognized for care of Heart Failure, Nonalcoholic Steatohepatitis, Atrial Fibrillation, Non-alcoholic Fatty Liver Disease, Cancer and other specialties. Virginia Commonwealth University is involved with conducting 828 clinical trials across 1,148 conditions. There are 79 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Keri Maher.

Top PIs

Clinical Trials running at Virginia Commonwealth University

Breast Cancer

Myotonic Dystrophy

Stroke

Bipolar Disorder

Duchenne Muscular Dystrophy

Heart Failure

Cystic Fibrosis

Cancer

Atrial Fibrillation

Traumatic Brain Injury

Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab

for Triple Negative Breast Cancer

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Recruiting

2 awards

Phase 3

6 criteria

Image of trial facility.

Hormone Therapy

for Breast Cancer

This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups: Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery. Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Ribociclib + Endocrine Therapy

for Breast Cancer Recurrence

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

Recruiting

1 award

Phase 2

12 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Virginia Commonwealth University?

Where is Virginia Commonwealth University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Virginia Commonwealth University accept?

What awards or recognition has Virginia Commonwealth University received?